Delving into the Latest Updates on Transdermal Delivery Solutions Corp. with Synapse

Overview

This study is a continuation of previous studies done in healthy volunteers to prove the efficacy of delivering Testosterone, the male hormone, rapidly across intact skin in s series of doses from low to high in men with low-to-no natural testosterone production to measure their response to the varying doses. The results of this study will inform further studies which will be longer in length, as to the starting doses. The study will be conducted in London, U.K. at the Advanced Therapies Centre, The London Clinic.

Start Date01 Jun 2025

Sponsor / Collaborator

Transdermal Delivery Solutions Corp.

NCT04857320

/ CompletedEarly Phase 1

A Physician-Initiated Randomised, Multiple-Dose, Single Period, Phase II Dose Ranging Study to Examine Transdermal Human Insulin In Adult Healthy Volunteer Patients

Bio-fermentation produced Human insulin is available without prescription in the U.S. This study is a physician-initiated trial of a formula enabling transdermal delivery of human insulin.

Start Date12 Mar 2021

Sponsor / Collaborator

Transdermal Delivery Solutions Corp.

[+1]

100 Clinical Results associated with Transdermal Delivery Solutions Corp.

Login to view more data

0 Patents (Medical) associated with Transdermal Delivery Solutions Corp.

Login to view more data

1

Literatures (Medical) associated with Transdermal Delivery Solutions Corp.

Drug Development & Delivery

New frontiers in transdermal drug delivery

Author: Alam, Chandan A. S. ; Kirby, Kenneth B.

A review.The advantages of a non-invasive method of drug delivery that offers both convenience and efficiency already outweigh the more traditional methods of oral delivery and hypodermic needles as the process eliminates gastrointestinal toxicity and first-pass metabolism associated with the more conventional techniques.Fentanyl, 2 anti-parkinson drugs, a bladder incontinence drug, and nitroglycerin transdermal solutions have been approved by the FDA.

1

News (Medical) associated with Transdermal Delivery Solutions Corp.

24 May 2021

·www.massdevice.com

Titan Medical names strategy VP

Titan Medical (TSX:TMD;OTC:TITFX) announced today that it appointed Deepak Basra as its VP of strategy and business development. In the newly created role, Basra’s responsibilities include overseeing Toronto-based Titan’s corporate development and strategic planning, according to a news release. Basra joins the company as a veteran of more than 20 years in global business development and mergers & acquisitions, having most recently held the role of SVP with Cortland Advisers, an M&A advisory firm. He previously served as board director & VP of strategy & business development at Transdermal Delivery Solutions. Before that, he operated as head of business development & licensing for Covidien’s vascular therapies division. Before Covidien, Basra served as SVP of strategy & business development at Smith+Nephew and held several roles at Cable & Wireless, British Telecommunications and Phillips. “We are thrilled to welcome Deepak to Titan. His wealth of knowledge and experience in business development and strategic partnerships will be instrumental in growing Titan,” Titan Medical president & CEO David McNally said in the release. “We look forward to Deepak’s contributions as we execute on our vision of advancing our Enos robotic single access surgery system.”

Acquisition

100 Deals associated with Transdermal Delivery Solutions Corp.

Login to view more data

100 Translational Medicine associated with Transdermal Delivery Solutions Corp.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 12 Mar 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

1

Login to view more data